Innovus Pharmaceuticals Inc. (fka INNV)

[jtaylor68]

RB#1, read:

The Company’s relationship with WWPIL for FlutiCare™ allows Innovus Pharma to launch the product in the U.S. on a shorter timeline instead of waiting for the approval of the first ANDA. In addition, Innovus Pharma believes that having two manufacturers, of which WWPIL is the sole manufacturer for FlutiCare™ in the U.S. market, is an advantage to ensure continuous product availability.

So, to reiterate, they commit to batches until 2018/19, because West-Ward is there to bring FlutiCare to the US Americans exclusively.
The other ANDA will supply FlutiCare be for the rest of the world.
This also debunks your claim that the West-Ward deal is just an expensive temporary solution out of desperation.